UBS maintains a 'Neutral' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target lowered from $20 to $17.

UBS analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE